HEMATOLOGY

Remote monitoring enhances infection management in hematologic malignancies, reducing hospitalizations and improving patient communication for better outcomes.

A new triplet therapy combining tagraxofusp, azacitidine, and venetoclax shows promising response rates and transplant potential for BPDCN patients.

During a live event, Praneeth Baratam, MBBS, discussed long-term data from a trial comparing luspatercept with epoetin alfa in low-risk myelodysplastic syndromes.

During a live event, Praneeth Baratam, MBBS, discussed the molecular factors that affect staging of lower-risk myelodysplastic syndromes.

The FDA has approved daratumumab and hyaluronidase plus chemotherapy for treating patients with newly diagnosed light chain amyloidosis.

New response criteria for acute GVHD enhance prediction of nonrelapse mortality, potentially transforming clinical trial designs and treatment evaluations.

During a live event, Hannah Choe, MD, and event participants discuss steroid-dependent chronic GVHD, favoring adding therapy over increasing steroids.

During a live event, Taha Al-Juhaishi, MD, discussed long-term outcomes of treating blastic plasmacytoid dendritic cell neoplasm and how to navigate toxicities and transplant.

During a live event, Raajit K. Rampal, MD, PhD, discussed ropeginterferon's potential to reduce JAK2 allele burden in low-risk polycythemia vera.

During a live event, Raajit K. Rampal, MD, PhD, discusses managing a patient with low-risk polycythemia vera.

During a live event, Taha Al-Juhaishi, MD, discussed his experience treating blastic plasmacytoid dendritic cell neoplasm and getting patients to allogeneic transplant.

The CAR-T treatment GLPG5101 received the FDA's RMAT designation by showing promising efficacy with rapid delivery and low toxicity in mantle cell lymphoma.

Explore the latest advancements in immunotherapies for T-cell lymphoma, addressing unique challenges and promising new treatment options.

During a live event, Thomas LeBlanc, MD, MA, discussed dose escalation of luspatercept in myelodysplastic syndromes and response to treatment based on mutational analyses.

Recent studies reveal promising outcomes for discontinuing TKI therapy in select patients with Philadelphia chromosome-positive acute lymphoblastic leukemia, suggesting potential long-term remission.

During a live event, Thomas LeBlanc, MD, MA, discussed the outcomes of the COMMANDS trial of luspatercept in myelodysplastic syndromes.

SENTI-202, a groundbreaking CAR NK-cell therapy, targets relapsed/refractory AML, offering hope for patients with limited treatment options.

During a live event, Gary J. Schiller, MD, explored the outcomes of the phase 1/2 trial of tagraxofusp-erzs in patients with blastic plasmacytoid dendritic cell neoplasm.

Abhishek Maiti, MD, discussed the EVICTION trial in AML and results presented during the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting.

During a live event, Gary J. Schiller, MD, reviewed the diagnostics and characteristics of blastic plasmacytoid dendritic cell neoplasm.

Cohort 1 of the GTB-3650 phase 1 trial completed with no safety issues observed in patients with CD33-expressing hematologic malignancies.

Olalekan O Oluwole, MD, MBBS, discussed a study on cytokine release syndrome and neurological events post axicabtagene ciloleucel in large B-cell lymphoma.

During a live event, Chris Benton, MD, discussed the focus on anemia management, reducing transfusions, and improving quality of life in MDS.

SGX301 has shown rapid and sustained benefit in early cutaneous T-cell lymphoma in an investigator-initiated study, with good safety.